Skip to main content
Erschienen in: Der Internist 10/2006

01.10.2006 | Schwerpunkt: Herzrhythmusstörungen

Moderne Pharmakotherapie bei supraventrikulären und ventrikulären Herzrhythmusstörungen

Ein Update zur konventionellen Therapie

verfasst von: D. Steven, B. Lutomsky, T. Rostock, Prof. Dr. S. Willems

Erschienen in: Die Innere Medizin | Ausgabe 10/2006

Einloggen, um Zugang zu erhalten

Zusammenfassung

Bei der Therapie supraventrikulärer Herzrhythmusstörungen haben sich in den letzten Jahren tief greifende Veränderungen ergeben: nichtmedikamentöse Strategien werden frühzeitiger eingesetzt und haben teilweise die medikamentösen Verfahren abgelöst. Häufig dient die medikamentöse Therapie, die über viele Jahre den Goldstandard darstellte, nur noch als Überbrückung bis zur kurativen Therapie durch Katheterablation des arrhythmogenen Substrates. Ein weiterer Schwerpunkt ist die adjuvante antiarrhythmische Therapie bei Patienten mit Cardioverter-Defibrillatoren. Bei der Akut- und Dauertherapie bestimmter Herzrhythmusstörungen, wie z. B. dem Vorhofflimmern, sind medikamentöse Ansätze unverzichtbar und weiterhin als primäre Therapie etabliert. Pharmaka, die zur Behandlung von Herzrhythmusstörungen eingesetzt werden, sind im Hinblick auf Struktur, Wirkmechanismus, potenzielle Nebenwirkungen und Interaktionen heterogen. Ihr Einsatz sollte nur bei strenger Indikationsstellung und engmaschiger kardiologischer Überwachung erfolgen. Angesichts ihrer häufig begrenzten therapeutischen Wirksamkeit ist die Nutzen-Risiko-Relation dieser Therapie besonders kritisch zu prüfen.
Literatur
1.
Zurück zum Zitat Alboni P, Botto GL, Baldi N et al. (2004) Outpatient treatment of recent-onset atrial fibrillation with the „pill-in-the-pocket“ approach. N Engl J Med 351(23): 2384–2391CrossRefPubMed Alboni P, Botto GL, Baldi N et al. (2004) Outpatient treatment of recent-onset atrial fibrillation with the „pill-in-the-pocket“ approach. N Engl J Med 351(23): 2384–2391CrossRefPubMed
2.
Zurück zum Zitat Anderson JL, Gilbert EM, Alpert BL et al. (1989) Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Flecainide Supraventricular Tachycardia Study Group. Circulation 80(6): 1557–1570PubMed Anderson JL, Gilbert EM, Alpert BL et al. (1989) Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Flecainide Supraventricular Tachycardia Study Group. Circulation 80(6): 1557–1570PubMed
3.
Zurück zum Zitat Bardy GH, Lee KL, Mark DB et al. (2005) Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352(3): 225–237CrossRefPubMed Bardy GH, Lee KL, Mark DB et al. (2005) Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352(3): 225–237CrossRefPubMed
4.
Zurück zum Zitat Bianconi L, Mennuni M (1998) Comparison between propafenone and digoxin administered intravenously to patients with acute atrial fibrillation. Am J Cardiol 82(5): 584–588CrossRefPubMed Bianconi L, Mennuni M (1998) Comparison between propafenone and digoxin administered intravenously to patients with acute atrial fibrillation. Am J Cardiol 82(5): 584–588CrossRefPubMed
5.
Zurück zum Zitat Bigger JT Jr, Fleiss JL, Kleiger R et al. (1984) The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. Circulation 69(2): 250–258PubMed Bigger JT Jr, Fleiss JL, Kleiger R et al. (1984) The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. Circulation 69(2): 250–258PubMed
6.
Zurück zum Zitat Blomstrom-Lundqvist C, Scheinman MM et al. (2003) ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias – executive summary: a report of the American College of Cardiology/American HeartAssociation Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines(Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias) Developed in collaboration with NASPE-Heart Rhythm Society. Eur Heart J 24(20): 1857–1897CrossRef Blomstrom-Lundqvist C, Scheinman MM et al. (2003) ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias – executive summary: a report of the American College of Cardiology/American HeartAssociation Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines(Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias) Developed in collaboration with NASPE-Heart Rhythm Society. Eur Heart J 24(20): 1857–1897CrossRef
7.
Zurück zum Zitat Capucci A, Boriani G, Rubino I et al. (1994) A controlled study on oral propafenone versus digoxin plus quinidine in converting recent onset atrial fibrillation to sinus rhythm. Int J Cardiol 43(3): 305–313CrossRefPubMed Capucci A, Boriani G, Rubino I et al. (1994) A controlled study on oral propafenone versus digoxin plus quinidine in converting recent onset atrial fibrillation to sinus rhythm. Int J Cardiol 43(3): 305–313CrossRefPubMed
8.
Zurück zum Zitat Connolly SJ, Hoffert DL (1989) Usefulness of propafenone for recurrent paroxysmal atrial fibrillation. Am J Cardiol 63(12): 817–819CrossRefPubMed Connolly SJ, Hoffert DL (1989) Usefulness of propafenone for recurrent paroxysmal atrial fibrillation. Am J Cardiol 63(12): 817–819CrossRefPubMed
9.
Zurück zum Zitat Connolly SJ, Gent M, Roberts RS et al. (2000) Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 101(11): 1297–1302PubMed Connolly SJ, Gent M, Roberts RS et al. (2000) Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 101(11): 1297–1302PubMed
10.
Zurück zum Zitat Connolly SJ, Hallstrom AP, Cappato R et al. (2000) Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J 21(24): 2071–2078CrossRefPubMed Connolly SJ, Hallstrom AP, Cappato R et al. (2000) Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J 21(24): 2071–2078CrossRefPubMed
11.
Zurück zum Zitat Connolly SJ, Dorian P, Roberts RS et al. (2006) Comparison of (beta)-Blockers, Amiodarone Plus (beta)-Blockers, or Sotalol for Prevention of Shocks From Implantable Cardioverter Defibrillators: The OPTIC Study: a randomized trial. JAMA 295(2): 165–171CrossRefPubMed Connolly SJ, Dorian P, Roberts RS et al. (2006) Comparison of (beta)-Blockers, Amiodarone Plus (beta)-Blockers, or Sotalol for Prevention of Shocks From Implantable Cardioverter Defibrillators: The OPTIC Study: a randomized trial. JAMA 295(2): 165–171CrossRefPubMed
12.
Zurück zum Zitat Danias P, Caulfield TA, Weigner MJ et al. (1998) Likelihood of spontaneous conversion of atrial fibrillation to sinus rhythm. J Am College Cardiol 31(3): 588–592CrossRef Danias P, Caulfield TA, Weigner MJ et al. (1998) Likelihood of spontaneous conversion of atrial fibrillation to sinus rhythm. J Am College Cardiol 31(3): 588–592CrossRef
13.
Zurück zum Zitat Echt DS, Liebson PR, Mitchell LB et al. (1991) Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 324(12): 781–788PubMed Echt DS, Liebson PR, Mitchell LB et al. (1991) Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 324(12): 781–788PubMed
14.
Zurück zum Zitat Epstein AE, Hallstrom AP, Rogers WJ et al. (1993) Mortality following ventricular arrhythmia suppression by encainide, flecainide, and moricizine after myocardial infarction. The original design concept of the Cardiac Arrhythmia Suppression Trial (CAST). JAMA 270(20): 2451–2455CrossRefPubMed Epstein AE, Hallstrom AP, Rogers WJ et al. (1993) Mortality following ventricular arrhythmia suppression by encainide, flecainide, and moricizine after myocardial infarction. The original design concept of the Cardiac Arrhythmia Suppression Trial (CAST). JAMA 270(20): 2451–2455CrossRefPubMed
15.
Zurück zum Zitat Fetsch T, Bauer P, Engberding R et al. (2004) Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. Eur Heart J 25(16): 1385–1394CrossRefPubMed Fetsch T, Bauer P, Engberding R et al. (2004) Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. Eur Heart J 25(16): 1385–1394CrossRefPubMed
15b.
Zurück zum Zitat Fuster V, Ryden LE, Cannom DS et al. ACC/AHA/ESC (2006) Guidelines for the Management of Patients With Atrial Fibrillation-Executive Summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). Journal of the American College of Cardiology 2006 August 15; 48(4): 854–906 Fuster V, Ryden LE, Cannom DS et al. ACC/AHA/ESC (2006) Guidelines for the Management of Patients With Atrial Fibrillation-Executive Summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). Journal of the American College of Cardiology 2006 August 15; 48(4): 854–906
16.
Zurück zum Zitat Gilman JK, Jalal S, Naccarelli GV (1994) Predicting and preventing sudden death from cardiac causes. Circulation 90(2): 1083–1092PubMed Gilman JK, Jalal S, Naccarelli GV (1994) Predicting and preventing sudden death from cardiac causes. Circulation 90(2): 1083–1092PubMed
17.
Zurück zum Zitat Go AS, Hylek EM, Phillips KA et al. (2001) Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 285(18): 2370–2375CrossRefPubMed Go AS, Hylek EM, Phillips KA et al. (2001) Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 285(18): 2370–2375CrossRefPubMed
18.
Zurück zum Zitat Goldberg AS, Bathina MN, Mickelsen S et al. (2002) Long-term outcomes on quality-of-life and health care costs in patients with supraventricular tachycardia (radiofrequency catheter ablation versus medical therapy). Am J Cardiol 89(9): 1120–1123CrossRefPubMed Goldberg AS, Bathina MN, Mickelsen S et al. (2002) Long-term outcomes on quality-of-life and health care costs in patients with supraventricular tachycardia (radiofrequency catheter ablation versus medical therapy). Am J Cardiol 89(9): 1120–1123CrossRefPubMed
19.
Zurück zum Zitat Greene HL (1993) The CASCADE Study: randomized antiarrhythmic drug therapy in survivors of cardiac arrest in Seattle. CASCADE Investigators. Am J Cardiol 72(16): 70F-4FCrossRefPubMed Greene HL (1993) The CASCADE Study: randomized antiarrhythmic drug therapy in survivors of cardiac arrest in Seattle. CASCADE Investigators. Am J Cardiol 72(16): 70F-4FCrossRefPubMed
20.
Zurück zum Zitat Hohnloser SH, Kuck KH, Lilienthal J (2000) Rhythm or rate control in atrial fibrillation--Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 356(9244): 1789–1794CrossRefPubMed Hohnloser SH, Kuck KH, Lilienthal J (2000) Rhythm or rate control in atrial fibrillation--Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 356(9244): 1789–1794CrossRefPubMed
21.
Zurück zum Zitat Hohnloser SH, Singh BN (1995) Proarrhythmia with class III antiarrhythmic drugs: definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications. J Cardiovasc Electrophysiol 6(10 Pt 2): 920–936PubMed Hohnloser SH, Singh BN (1995) Proarrhythmia with class III antiarrhythmic drugs: definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications. J Cardiovasc Electrophysiol 6(10 Pt 2): 920–936PubMed
22.
Zurück zum Zitat Hsu LF, Jais P, Sanders P et al. (2004) Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med 351(23): 2373–2383CrossRefPubMed Hsu LF, Jais P, Sanders P et al. (2004) Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med 351(23): 2373–2383CrossRefPubMed
23.
Zurück zum Zitat Joseph AP, Ward MR (2000) A prospective, randomized controlled trial comparing the efficacy and safety of Sotalol, Amiodarone, and Digoxin for the reversion of new-onset atrial fibrillation. Ann Emergency Med 36(1): 1–9CrossRef Joseph AP, Ward MR (2000) A prospective, randomized controlled trial comparing the efficacy and safety of Sotalol, Amiodarone, and Digoxin for the reversion of new-onset atrial fibrillation. Ann Emergency Med 36(1): 1–9CrossRef
24.
Zurück zum Zitat Juul-Moller S, Edvardsson N, Rehnqvist-Ahlberg N (1990) Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation 1990 82(6): 1932–1939 Juul-Moller S, Edvardsson N, Rehnqvist-Ahlberg N (1990) Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation 1990 82(6): 1932–1939
25.
Zurück zum Zitat Kirchhof P, Fetsch T, Hanrath P et al. (2005) Targeted pharmacological reversal of electrical remodeling after cardioversion – rationale and design of the Flecainide Short-Long (Flec-SL) trial. Am Heart J 150(5): 899CrossRef Kirchhof P, Fetsch T, Hanrath P et al. (2005) Targeted pharmacological reversal of electrical remodeling after cardioversion – rationale and design of the Flecainide Short-Long (Flec-SL) trial. Am Heart J 150(5): 899CrossRef
26.
Zurück zum Zitat Kuck KH, Cappato R, Siebels J, Ruppel R (2000) Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest : The Cardiac Arrest Study Hamburg (CASH). Circulation 102(7): 748–754PubMed Kuck KH, Cappato R, Siebels J, Ruppel R (2000) Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest : The Cardiac Arrest Study Hamburg (CASH). Circulation 102(7): 748–754PubMed
27.
Zurück zum Zitat Kuhlkamp V, Mewis C, Mermi J et al. (1999) Suppression of sustained ventricular tachyarrhythmias: a comparison of d,l-sotalol with no antiarrhythmic drug treatment. J Am College Cardiol 33(1): 46–52CrossRef Kuhlkamp V, Mewis C, Mermi J et al. (1999) Suppression of sustained ventricular tachyarrhythmias: a comparison of d,l-sotalol with no antiarrhythmic drug treatment. J Am College Cardiol 33(1): 46–52CrossRef
28.
Zurück zum Zitat Kuhlkamp V, Schirdewan A, Stangl K et al. (2000) Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 36(1): 139–146CrossRefPubMed Kuhlkamp V, Schirdewan A, Stangl K et al. (2000) Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 36(1): 139–146CrossRefPubMed
29.
Zurück zum Zitat Li D, Shinagawa K, Pang L et al. (2001) Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 104(21): 2608–2614PubMed Li D, Shinagawa K, Pang L et al. (2001) Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 104(21): 2608–2614PubMed
30.
Zurück zum Zitat Madrid AH, Peng J, Zamora J et al. (2004) The role of angiotensin receptor blockers and/or angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation in patients with cardiovascular diseases: meta-analysis of randomized controlled clinical trials. Pacing Clin Electrophysiol 27(10): 1405–1410CrossRefPubMed Madrid AH, Peng J, Zamora J et al. (2004) The role of angiotensin receptor blockers and/or angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation in patients with cardiovascular diseases: meta-analysis of randomized controlled clinical trials. Pacing Clin Electrophysiol 27(10): 1405–1410CrossRefPubMed
31.
Zurück zum Zitat Marcus FI (1990) The hazards of using type 1C antiarrhythmic drugs for the treatment of paroxysmal atrial fibrillation. Am J Cardiol 66(3): 366–367CrossRefPubMed Marcus FI (1990) The hazards of using type 1C antiarrhythmic drugs for the treatment of paroxysmal atrial fibrillation. Am J Cardiol 66(3): 366–367CrossRefPubMed
32.
Zurück zum Zitat Mason JW, The Electrophysiologic Study versus Electrocardiographic Monitoring Investigators (1993) A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. N Engl J Med 329(7): 452–458CrossRefPubMed Mason JW, The Electrophysiologic Study versus Electrocardiographic Monitoring Investigators (1993) A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. N Engl J Med 329(7): 452–458CrossRefPubMed
33.
Zurück zum Zitat Mason JW, The Electrophysiologic Study versus Electrocardiographic Monitoring Investigators (1993) A comparison of electrophysiologic testing with holter monitoring to predict antiarrhythmic-drug efficacy for ventricular tachyarrhythmias. N Engl J Med 329(7): 445–451CrossRefPubMed Mason JW, The Electrophysiologic Study versus Electrocardiographic Monitoring Investigators (1993) A comparison of electrophysiologic testing with holter monitoring to predict antiarrhythmic-drug efficacy for ventricular tachyarrhythmias. N Engl J Med 329(7): 445–451CrossRefPubMed
34.
Zurück zum Zitat Moss AJ, Zareba W, Hall WJ et al. (2002) Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346(12): 877–883CrossRefPubMed Moss AJ, Zareba W, Hall WJ et al. (2002) Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346(12): 877–883CrossRefPubMed
35.
36.
Zurück zum Zitat Natale A, Newby KH, Pisano E et al. (2000) Prospective randomized comparison of antiarrhythmic therapy versus first-line radiofrequency ablation in patients with atrial flutter. J Am College Cardiol 35(7): 1898–1904CrossRef Natale A, Newby KH, Pisano E et al. (2000) Prospective randomized comparison of antiarrhythmic therapy versus first-line radiofrequency ablation in patients with atrial flutter. J Am College Cardiol 35(7): 1898–1904CrossRef
37.
Zurück zum Zitat Page RL, Wilkinson WE, Clair WK et al. (1994) Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. Circulation 89(1): 224–227PubMed Page RL, Wilkinson WE, Clair WK et al. (1994) Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. Circulation 89(1): 224–227PubMed
38.
Zurück zum Zitat Pantos C, Mourouzis I, Delbruyere M et al. (2002) Effects of dronedarone and amiodarone on plasma thyroid hormones and on the basal and postischemic performance of the isolated rat heart. Eur J Pharmacol 444(3): 191–196CrossRefPubMed Pantos C, Mourouzis I, Delbruyere M et al. (2002) Effects of dronedarone and amiodarone on plasma thyroid hormones and on the basal and postischemic performance of the isolated rat heart. Eur J Pharmacol 444(3): 191–196CrossRefPubMed
39.
Zurück zum Zitat Pedersen OD, Bagger H, Keller N et al. (2001) Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish Investigations of Arrhythmia and Mortality ON Dofetilide (DIAMOND) Substudy. Circulation 104(3): 292–296PubMed Pedersen OD, Bagger H, Keller N et al. (2001) Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish Investigations of Arrhythmia and Mortality ON Dofetilide (DIAMOND) Substudy. Circulation 104(3): 292–296PubMed
40.
Zurück zum Zitat Pfeffer MA, Braunwald E, Moye LA et al. (1992) Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 327(10): 669–677PubMed Pfeffer MA, Braunwald E, Moye LA et al. (1992) Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 327(10): 669–677PubMed
41.
Zurück zum Zitat Roy D, Talajic M, Dorian P et al. (2000) Amiodarone to prevent recurrence of atrial fibrillation. N Engl J Med 342(13): 913–920CrossRefPubMed Roy D, Talajic M, Dorian P et al. (2000) Amiodarone to prevent recurrence of atrial fibrillation. N Engl J Med 342(13): 913–920CrossRefPubMed
42.
Zurück zum Zitat Singh SN, Singh BN, Reda DJ et al. (2003) Comparison of sotalol versus amiodarone in maintaining stability of sinus rhythm in patients with atrial fibrillation (Sotalol-Amiodarone Fibrillation Efficacy Trial [Safe-T]). Am J Cardiol 92(4): 468–472CrossRefPubMed Singh SN, Singh BN, Reda DJ et al. (2003) Comparison of sotalol versus amiodarone in maintaining stability of sinus rhythm in patients with atrial fibrillation (Sotalol-Amiodarone Fibrillation Efficacy Trial [Safe-T]). Am J Cardiol 92(4): 468–472CrossRefPubMed
43.
Zurück zum Zitat The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators (1997) A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 337(22): 1576–1583CrossRefPubMed The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators (1997) A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 337(22): 1576–1583CrossRefPubMed
44.
Zurück zum Zitat The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators (2002) A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347(23): 1825–1833PubMed The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators (2002) A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347(23): 1825–1833PubMed
45.
Zurück zum Zitat Van Gelder IC, Hagens VE, Bosker HA et al. (2002) A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 347(23): 1834–1840CrossRefPubMed Van Gelder IC, Hagens VE, Bosker HA et al. (2002) A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 347(23): 1834–1840CrossRefPubMed
Metadaten
Titel
Moderne Pharmakotherapie bei supraventrikulären und ventrikulären Herzrhythmusstörungen
Ein Update zur konventionellen Therapie
verfasst von
D. Steven
B. Lutomsky
T. Rostock
Prof. Dr. S. Willems
Publikationsdatum
01.10.2006
Verlag
Springer-Verlag
Erschienen in
Die Innere Medizin / Ausgabe 10/2006
Print ISSN: 2731-7080
Elektronische ISSN: 2731-7099
DOI
https://doi.org/10.1007/s00108-006-1709-5

Weitere Artikel der Ausgabe 10/2006

Der Internist 10/2006 Zur Ausgabe

Schwerpunkt: Herzrhythmusstörungen

Moderne Herzschrittmachertherapie

CME Weiterbildung · Zertifizierte Fortbildung

Systemische Sklerose

Schwerpunkt: Herzrhythmusstörungen

Vorhofflimmern

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.